New indication for Sanofi's non-calcium-phosphorus-containing binding agent Novila (R) was launched

Shanghai, November 2, 2021/PRNewswire/ - Recently, Sanofi, the world's leading biopharmaceutical company, announced that Novila® (sevelamer carbonate) was officially listed in China for a new indication for treatment that has not been carried out Hyperphosphatemia in adults with chronic kidney disease on dialysis

Professor Jiang Gengru, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, said: “Hyperphosphatemia in patients with chronic kidney disease is associated with adverse outcomes, including vascular calcification, chronic kidney disease progression, and increased risk of death [i].

Professor Li Guisen from Sichuan Provincial People’s Hospital said: “The approval of the new indication for Novella® brings a new treatment plan for patients with non-dialysis chronic kidney disease and hyperphosphatemia, and also provides us with better clinical treatment options.

Professor Zuo Li from the People's Hospital of Peking University said: "The launch of Novila® for non-dialysis hyperphosphatemia indications fills the gap in the domestic market that there is no non-calcium-phosphorus binder for non-dialysis chronic kidney disease hyperphosphatemia

Professor Liang Xinling from Guangdong Provincial People’s Hospital said: “The approval of Novila® in the non-transparent indication for CKD gives us a more scientific approach to the management of early calcium and phosphorus metabolism disorders in CKD, so that the blood phosphorus management of CKD-MBD can be truly implemented.

Professor Chen Wei from the First Affiliated Hospital of Sun Yat-Sen University said: "The results of a Phase III clinical study (RECOVER) conducted in Chinese patients with non-dialysis chronic kidney disease and hyperphosphatemia confirmed the effectiveness and safety of Novila®

Ms.

With the increasing trend of population aging, the incidence of chronic kidney disease in China has been on the rise in recent years

Hyperphosphatemia is one of the important complications of patients with chronic kidney disease

[i] Vervloet MG, Sezer S, Massy ZA, et al.

Cozzolino M, et al.

Wei Qing, et al.

[ii] Xueqing Yu,Nephrology Dialysis Transplantation, Volume 35, Issue Supplement_3, June 2020, gfaa142.

[iii] Zhang, Luxia, et al.

[iv] Chen Menghua, Yu Xueqing.

[v] Zhou C, et al.

About Sanofi China

Sanofi is a leading global biopharmaceutical company focusing on human health
.
As one of the first multinational companies to enter China after the reform and opening up, Sanofi established an office in China in 1982
.
Sanofi China's diversified business covers pharmaceuticals, human vaccines and consumer healthcare
.
In China, Sanofi has 12 offices, 3 production bases, 4 major R&D bases and 1 digital innovation center
.
Sanofi is committed to accelerating the introduction of innovative drugs and vaccines into China, leading the way in digital innovation, so as to meet the health needs of the vast majority of Chinese people
.

For more information, please visit or follow the "Sanofi China" WeChat official account and "Sanofi" LinkedIn account
.

About Sanofi

Sanofi is committed to helping people cope with health challenges
.
We are a global biopharmaceutical company focused on human health
.
We use vaccines to prevent diseases, and provide innovative treatments to alleviate pain and distress
.
We help a very small number of people suffering from rare diseases, and also support tens of millions of patients suffering from chronic diseases for a long time
.

Sanofi has more than 100,000 employees in more than 100 countries and is committed to transforming scientific innovation into medical and health solutions
.

Sanofi, Empowering Life Sanofi, Empowering Life

Sanofi's forward-looking statements

This press release contains forward-looking statements
.
Forward-looking statements are not statements of historical facts
.
These statements include forecasts and estimates and basic assumptions, statements about the company's future plans, goals, and intentions, prospects for future financial conditions, events, operations, services, product development and potential, and statements about future performance
.
Generally, words such as "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions can be used as the basis for determining forward-looking statements
.
Although Sanofi’s management believes that the expectations reflected in this forward-looking statement are reasonable, investors should still note that these forward-looking information and statements are subject to many risks and uncertainties, many of which are difficult to predict and are generally not Sanofi controls, which may cause actual results and developments to differ materially from those expressed, implied or predicted in forward-looking information and statements
.
These risks and uncertainties mainly include the inherent uncertainties in research and development, future clinical data and analysis, including the data and analysis performed after the product is marketed, and the decisions of regulatory authorities, such as the US Food and Drug Administration The decision of the Agency or the European Medicines Agency on whether and when to approve the marketing of any drugs, medical devices or biological products that may be filed for candidate products, as well as the product labeling and other products that may affect the availability and commercial potential of such candidate products Decisions on matters such as the possibility of commercial success of approved candidate products, the approval of future alternative therapies and their commercial success, the group will benefit from external growth opportunities and completion of related transactions and/or obtaining regulatory approvals Capacity, risks associated with intellectual property rights and any related pending or future litigation and the final outcome of such litigation, turbulent economic and market conditions, the impact of global destruction including global epidemics, exchange rate trends and general Interest rates, cost control policies and the resulting results, the average number of issued shares, and Sanofi’s publicly submitted reports to the United States Securities and Exchange Commission (SEC) and the French Financial Market Authority (AMF) have discussed or The clear part, including the "risk factors" and "warning of forward-looking statements" in Sanofi's annual report (as of December 31, 2020) listed in Table 20-F
.
Unless applicable legal requirements exist, Sanofi assumes no obligation to update or revise any forward-looking information and statements
.

Source: Sanofi China